Rhabdomyosarcoma (RMS) is the commonest soft-tissue sarcoma in childhood and is characterized by expression of myogenic proteins, including the transcription factors MyoD and myogenin. There are two main subgroups, embryonal RMS and alveolar RMS (ARMS). Most ARMS are associated with chromosomal translocations that have breakpoints in introns of either PAX3 or PAX7, and FOXO1A. These translocations create chimeric transcription factors termed PAX3/FOXO1A and PAX7/FOXO1A respectively. Upon ectopic PAX3/FOXO1A expression, together with other genetic manipulation in mice, both differentiating myoblasts and satellite cells (the resident stem cells of postnatal muscle) can give rise to tumours with ARMS characteristics. As PAX3 and PAX7 are part of transcriptional networks that regulate muscle stem cell function in utero and during early postnatal life, PAX3/FOXO1A and PAX7/FOXO1A may subvert normal PAX3 and PAX7 functions. Here we examined how PAX3/FOXO1A and PAX7/FOXO1A affect myogenesis in satellite cells. PAX3/FOXO1A or PAX7/FOXO1A inhibited myogenin expression and prevented terminal differentiation in murine satellite cells: the same effect as dominant-negative (DN) Pax3 or Pax7 constructs. The transcription of MyoD-target genes myogenin and muscle creatine kinase were suppressed by PAX3/FOXO1A or PAX7/ FOXO1A in C2C12 myogenic cells again as seen with Pax3/7DN. PAX3/FOXO1A or PAX7/FOXO1A did not inhibit the transcriptional activity of MyoD by perturbing MyoD expression, localization, phosphorylation or interaction with E-proteins. Chromatin immunoprecipitation on the myogenin promoter showed that PAX3/FOXO1A or PAX7/FOXO1A did not prevent MyoD from binding. However, PAX3/FOXO1A or PAX7/FOXO1A reduced occupation of the myogenin promoter by RNA polymerase II and decreased acetylation of histone H4, but did not directly bind to the myogenin promoter. Together, these observations reveal that PAX3/FOXO1A and PAX7/FOXO1A act to prevent myogenic differentiation via suppression of the transcriptional activation of MyoD-target genes.
INTRODUCTION
Rhabdomyosarcoma (RMS) is the commonest soft-tissue sarcoma in childhood, characterized by expression of myogenic genes. There are two main subgroups, embryonal RMS and alveolar RMS (ARMS), which are associated with distinct morphological, clinical and genetic characteristics. ARMS often contain t(2;13)(q35;q14) or t(1;13)(p36;q14) chromosomal translocations that encode a chimeric protein under the control of upstream regulatory elements and the promoter of the paired-box (Pax) transcription factors PAX3 or PAX7, containing the 5 0 -untranslated region and first seven exons of PAX3/7, fused to the last two exons and 3 0 -untranslated region of another transcription factor---FOXO1A. The resulting hybrid transcription factors PAX3/FOXO1A and PAX7/ FOXO1A (collectively called PAX/FOXO1A here) thus have the DNA-binding homeo-and paired-domains, and the octapeptide motif that mediates protein --protein interactions, of PAX3/7, fused to the potent transactivation domain of FOXO1A.
1 PAX/FOXO1A have enhanced protein stability, abundance, transcriptional activity and additional target sequences, 1, 2 and may subvert normal functions of PAX3/7 protein by deregulating the PAX3/7-downstream target genes. 3 --7 Both Pax3 and Pax7 are part of the transcriptional networks that control activation of the myogenic programme during skeletal muscle development. 8 Pax3-null mice have reduced/ absent trunk musculature, whereas the limb and diaphragm muscles completely fail to form, 8 and deletion of both Pax3 and Pax7 cause a loss of muscle progenitors and arrest of developmental myogenesis. 9 Conditional Pax7 inactivation shows that it is required for satellite cell function during early postnatal muscle growth. 10 Myogenic progression in satellite cells is controlled by the muscle-specific transcription factor MyoD, which can be directly regulated by Pax3 or Pax7, 11, 12 whereas myogenin is an early marker of differentiation, whose expression occurs concomitantly with downregulation of Pax7. 11, 13 Consistent with these observations MyoD is upregulated in embryos in which PAX3/FOXO1A has been targeted to a Pax3 allele, 14 and PAX3/ FOXO1A directly binds the MyoD distal regulatory region. 15 However, although MyoD is expressed in ARMS, it is transcriptionally inactive. 16, 17 These connections to the myogenic lineage implicate muscle stem cells as a potential cellular source of ARMS. Furthermore, ARMS often occurs in the vicinity of skeletal muscle in the extremities and trunk of adolescents and young adults. 18 --21 Work in mice indicates that upon ectopic expression of PAX3/ FOXO1A, together with other genetic manipulations, both presumed differentiating myoblasts (Mrf4/myf6-directed Cre) and Pax7-expressing (Pax7-directed Cre) cells can generate tumours with an ARMS phenotype, 22, 23 although they are unlikely to be the exclusive source. 24 As Pax7 is expressed in muscle satellite cells, 25 the resident stem cells of adult muscle, satellite cells are a good candidate for transformation into oncogenic cells in ARMS.
In myogenic cells, PAX3/FOXO1A generally inhibits differentiation, but it is unclear at which point it intervenes, or how. 2, 26 Importantly, MyoD is able to convert many non-muscle cell types to the myogenic lineage 27, 28 and PAX3/FOXO1A can activate MyoD in fibroblasts, but the degree of subsequent myogenic differentiation varies between studies from none, through to fusion into large multinucleated myotubes. 29 --31 PAX3/FOXO1A can also inhibit this MyoD-mediated conversion, 26, 29 but this effect is MyoD-specific, as PAX3/FOXO1A does not have substantial effects on myogenin-dependent myogenic conversion. 26 Here we investigated and directly compared the effects of PAX3/FOXO1A and PAX7/FOXO1A on satellite cell function, and how this effect is mediated. Constitutive PAX3/FOXO1A or PAX7/FOXO1A in activated satellite cells was compatible with MyoD expression, but myogenin was not induced and differentiation was blocked. The activity of the MyoD-target gene reporters, including myogenin, muscle creatine kinase (MCK) and p21, were all suppressed in C2 myoblasts, indicating that PAX/FOXO1A can inhibit the ability of MyoD to activate its transcriptional target genes. A similar suppression of reporter activity occurs with dominant-negative (DN) versions of Pax3 and Pax7. Various posttranslational mechanisms control the transcriptional activity of MyoD, 32 but PAX/FOXO1A did not affect MyoD localization, phosphorylation, or interaction with E-proteins. However, chromatin immunoprecipitation (ChIP) revealed that although PAX3/ FOXO1A or PAX7/FOXO1A did not affect MyoD binding to the myogenin promoter, it did reduce acetylation of histone H4 and occupation of the myogenin promoter by RNA polymerase II. Together, these observations show that PAX3/FOXO1A and PAX7/ FOXO1A suppress the transcriptional activation of MyoD-target genes to inhibit myogenic differentiation.
RESULTS
The Pax3 locus is active in a subset of quiescent satellite cells We have previously shown that the Pax3 locus is active in a subset of adult skeletal muscles. 11, 33 Here we examined the precise expression of the Pax3 locus and Pax7 in individual satellite cells. Myofibres were isolated from extensor digitorum longus (EDL), biceps, soleus, masseter and diaphragm of adult Pax3 GFP/ þ mice, and their associated satellite cells co-immunostained for enhanced green fluorescent protein (eGFP) (Pax3) and Pax7. 13 The Pax7-expressing satellite cells from the masseter and soleus did not express Pax3, whereas 7% of those from the EDL did. By contrast, 49% of satellite cells from biceps and 64% from diaphragm co-expressed eGFP (Pax3) and Pax7, with the vast majority of the reminder only expressing Pax7, as cells with just Pax3 were rare (Figures 1a and b ; Supplementary Figure S1A /B). Regarding their distribution, the majority of myofibres from biceps and diaphragm had associated satellite cells that co-immunostained for Pax7 and eGFP (Pax3) (Supplementary Figure S1B ). Myofibres were cultured to activate the associated satellite cells, but EDL-derived MyoD þ activated satellite cells remained eGFP-negative, showing that the Pax3 locus was not induced upon activation (Figures 1c --d) . Even in activated satellite cells from the biceps, most cells did not express eGFP (Figures 1c and e) .
Myogenic differentiation is inhibited by PAX3/FOXO1A or PAX7/ FOXO1A We used retroviral-mediated constitutive expression to examine the effects of PAX3/FOXO1A and PAX7/FOXO1A on myogenic progression in satellite cells from a muscle with few satellite cells with Pax3 locus activity (EDL), compared with one with many satellite cells with Pax3 locus activity (biceps). Cultured wildtype myofibres were exposed to pMSCV-IRES-PAX3/FOXO1A-eGFP (PAX3F-RV), pMSCV-IRES-PAX7/FOXO1A-eGFP (PAX7F-RV) or pMSCV-IRES-eGFP (control-RV) and fixed 48 h later.
Infected myofibre-associated satellite cells were identified by eGFP, and endogenous Pax7 was assayed using an antibody against the C-terminus (epitopes 352 --523), not present in PAX7/ FOXO1A. Co-immunostaining for eGFP and Pax7 (Figures 2a  and b) showed that more myofibre-associated cells expressing PAX3/FOXO1A (EDL 58.0 ± 8%; biceps 64 ± 10.5%) or PAX7/ FOXO1A (EDL 45.8 ± 13.7%; biceps 42.8 ± 8.2%) contained Pax7, compared with control-RV (EDL 24.4±0.1%; biceps 14.3±3.2% - Figure 2c ).
Co-immunostaining for either eGFP/MyoD or eGFP/myogenin showed that while PAX3F-RV-or PAX7F-RV-infected satellite cells maintained MyoD (Figure 3a) , induction of myogenin was inhibited ( Figure 3b ) [PAX3/FOXO1A (EDL 7.6±4.6%, biceps 6.9 ± 3.6%) and PAX7/FOXO1A (EDL 13.2 ± 1.5%, biceps 17 ± 5.8%) compared with control-RV (EDL 60.7 ± 0.5%; biceps 69.6±0.05%; Figures 3c --d) ]. MEF2 can co-operate with MyoD to activate MyoD-target genes, such a myogenin, during differentiation, 34, 35 but also failed to be upregulated in satellite cells expressing PAX3/FOXO1A or PAX7/FOXO1A (Supplementary- Figure S2 ).
Plating satellite cells allows the later stages of myogenic differentiation to be examined, such as fusion into multi-nucleated myotubes. To better understand how PAX/FOXO1A affects satellite cells, we directly compared PAX/FOXO1A with wild-type Pax3/7, together with Pax3DN and Pax7DN constructs, in which the transactivation domain has been replaced with the engrailed repressor domain. 36 Figure S4B ). PAX3/FOXO1A or PAX7/FOXO1A suppress transcriptional targets of MyoD To confirm that PAX3/7/FOXO1A is able to activate transcription through binding to the same consensus sequences as wild-type Pax3/7, we used the p34 reporter construct in which Tk-nlacZ is controlled by multimerized Pax3/7 binding sites. 12, 37 C2C12 cells were infected with retroviruses encoding PAX3/FOXO1A, PAX7/ FOXO1A, Pax3, Pax7, Pax3DN or Pax7DN, and then transiently transfected with p34 and Renilla-luciferase as control (Figure 5a ). Using the panel of Pax3/7 constructs allows direct comparison, and we found that PAX3/FOXO1A activated p34 more than Pax3, whereas PAX7/FOXO1A and Pax7 resulted in a similar increase compared with control-RV. Pax3DN or Pax7DN repressed reporter activity, as expected.
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Pax3 and Pax7 are upstream of MyoD in the genetic hierarchy that regulates myogenesis in embryo and adult. 11, 12, 14, 21, 38 Thus, PAX/FOXO1A may act by interfering with the ability of MyoD to activate its transcriptional target genes, and so, we also examined effects of PAX3/FOXO1A or PAX7/FOXO1A on several MyoDresponsive reporters. C2C12 cells were infected, then transiently transfected with the reporter construct and maintained in differentiation medium for 4 days. Activity of myogenin-luciferase or MCK-luciferase reporters were clearly suppressed by PAX3/ FOXO1A or PAX7/FOXO1A, to a similar extent as observed with Pax3DN or Pax7DN, whereas no reduction was measured with either Pax3 or Pax7 (Figures 5b and c) . A control dominantnegative MyoD construct (MyoDDN) 39 inhibited the MCK-reporter as expected (Figure 5c ).
MyoD also induces the cyclin-dependent kinase inhibitor p21 CIP1/WAF1 , a critical regulatory event for establishment of the post-mitotic state in myotubes. 40 --42 PAX3/FOXO1A or PAX7/ FOXO1A inhibited p21-luciferase reporter activity (Figure 5d ). Thus, PAX3/FOXO1A and PAX7/FOXO1A suppress the activity of at least three MyoD-responsive genes.
Direct effects of PAX3/FOXO1A or PAX7/FOXO1A on the MyoDtarget reporters in the absence of MyoD was assayed in C3H10T1/2 fibroblasts. Cells were infected, then transiently transfected with the reporter constructs and maintained in proliferation medium for 24 h before luciferase activity was measured. PAX3/ FOXO1A, PAX7/FOXO1A, Pax3 or Pax7 did not affect the basal activity of the myogenin-luciferase reporter in C3H10T1/2 fibroblasts ( Figure 5e ). PAX3/FOXO1A or PAX7/FOXO1A do not alter MyoD phosphorylation or interaction with E-proteins The ability of MyoD to regulate its transcriptional targets is regulated in multiple ways, including MyoD localization, phosphorylation or interaction with E-proteins, 43, 34 processes with which PAX3/FOXO1A or PAX7/FOXO1A could interfere. However, MyoD remained located in the nucleus in cells expressing PAX3/FOXO1A or PAX7/FOXO1A (Supplementary Figure S2) , and western blot analysis did not reveal changes to MyoD phosphorylation ( Figure 6a ). Dimerization of MyoD with E-protein (E12/47) is a required step to activate transcription and initiate muscle differentiation, and immunoblotting analysis showed that MyoD retained its ability to associate with E12/47protein in the presence of PAX3/FOXO1A or PAX7/FOXO1A (Figure 6b ).
MyoD transcriptional activity can be repressed by inhibitory proteins that physically interact with MyoD, whereas others act by indirect mechanisms, such as displacement of E-protein and competition for DNA. 34, 35 A forced dimer (MyoDBE) in which a peptide linker joins MyoD and E-protein together 39 was used to determine whether this could overcome PAX3/FOXO1A or PAX7/ FOXO1A. Stable C2C12 clones expressing MyoDBE were infected with PAX3F-RV or PAX7F-RV, and switched 24 h later to differentiation medium for 4 days. Co-immunostaining for eGFP and troponinT ( Figure 6c ) revealed that cells expressing PAX3/ FOXO1A or PAX7/FOXO1A generally did not fuse into multinucleated myotubes. Furthermore, in the presence of PAX3/ FOXO1A or PAX7/FOXO1A, MyoDBE was unable to activate myogenin-and MCK-luciferase reporters to the same levels as in control-RV infected cells (Figures 6d and e) . PAX3/FOXO1A or PAX7/FOXO1A decrease acetylation of histone H4 and RNA polymerase II occupation at the myogenin promoter To examine occupancy of the myogenin promoter in the presence of PAX3/FOXO1A or PAX7/FOXO1A, C2 myoblasts were infected with PAX3F-RV, PAX7F-RV or control retroviruses, and incubated in differentiation medium for 24 h once confluent. This point was chosen, as MyoD and myogenin transcript levels were high in control cells. Although MyoD was unchanged in PAX3-7/FOXO1A-expressing differentiating cells (Figure 7a ), myogenin transcription was inhibited (Figure 7b ).
To understand how PAX3/FOXO1A or PAX7/FOXO1A inhibits the activity of MyoD target genes, we examined whether they directly bind to the myogenin promoter using ChIP, as has recently been PAX3/FOXO1A and PAX7/FOXO1A inhibit MyoD-target genes F Calhabeu et al proposed. 44 Chromatin was prepared from C2 myoblasts after 24 h in differentiation medium. Neither PAX3/FOXO1A nor PAX7/FOXO1A were enriched at the myogenin locus (Figure 7c ). The verified binding site of the 145-bp regulatory element at À57.5 kb from Myf5 45,46 was used as a positive control and showed binding of both PAX3/FOXO1A and PAX7/FOXO1A (Figure 7d) .
Chromatin modification and recruitment of transcriptional regulatory proteins to the proximal myogenin promoter was also assessed by ChIP, to investigate if PAX3/FOXO1A or PAX7/FOXO1A altered chromatin remodelling and protein --DNA interaction at a MyoD-target gene. Binding of MyoD at the myogenin promoter was not affected by PAX3/FOXO1A or PAX7/FOXO1A (Figure 7e ). By contrast, the level of acetylation of core histone H4 was reduced (Figure 7f) , as was binding of RNA polymerase II to the myogenin promoter (Figure 7g ).
DISCUSSION
The cellular source of ARMS is unclear, but recent work indicates that mutations/chromosomal translocations in myogenic cells could be responsible in some cases. 22, 23 We therefore wished to understand the early effects of PAX/FOXO1A on satellite cell function, in a cell that may ultimately undergo transformation to establish an oncogenic phenotype.
Satellite cells are heterogeneous, for example, in their proliferation rates, clonogenic ability and myogenicity, 47 and so, certain subsets may be more pre-disposed to oncogenic transformation than others. Of relevance to ARMS, although all satellite cells express Pax7, 25 the Pax3 locus is only active in particular skeletal muscles in adult mouse. 11, 33 We found that even within these muscles though, the Pax3 locus is only active in a subset of their satellite cells. Although Pax3 and Pax7 distribution has not yet been characterized in detail in man, heterogeneity in Pax3 and Pax7 expression may have implications for oncogenic transformation. Therefore, the effects of PAX3/FOXO1A and PAX7/ FOXO1A were tested on populations of satellite cells with high (biceps) and low (EDL) numbers of satellite cells with clear Pax3 locus activity. Satellite cells from limb muscles were also used, as a high proportion of ARMS tumours (B39%) in man originate in the extremities. 19 Neither PAX3/FOXO1A nor PAX7/FOXO1A decreased expression of MyoD, but both drastically reduced the expression of myogenin, showing that the early steps of differentiation were inhibited, consistent with the general lack of myogenic differentiation seen in ARMS. However, the effects of PAX3/FOXO1A or PAX7/FOXO1A were the same in satellite cells from both EDL and biceps, so the levels of Pax3 locus activity did not overtly influence the outcome, although endogenous Pax3 levels in adult mouse muscle are negligible. 36, 48 Other studies in plated myogenic cells report either expression of myosin heavy chain but no fusion in perinatal mouse myoblasts, 2 or a drastic inhibition of myosin expression in C2 myoblasts. 26 In plated EDL or bicipital-derived satellite cells PAX3/FOXO1A and PAX7/FOXO1A inhibit MyoD-target genes F Calhabeu et al from adult mouse, we found that PAX/FOXO1A was compatible with MyoD expression, but inhibited both early (myogenin) and late (troponinT) markers of myogenic differentiation, as well as cell fusion into multinucleated myotubes. Differentiation was also prevented by dominant-negative Pax3/7DN constructs, but not by native Pax3/7 (although myotubes were generally smaller 36 ). As MyoD was unaffected by PAX/FOXO1A, yet, myogenin was clearly suppressed; the block on differentiation appears to be at the level of the ability of MyoD to activate its transcriptional target genes, of which myogenin is one. Therefore, we assayed the effects of PAX/FOXO1A on the activity of well-characterized MyoD-target gene reporter constructs in direct comparison with native Pax3/7 and Pax3/7DN. PAX/FOXO1A suppressed the activity of myogenin, and MCK reporters to a similar extent as Pax3/7DN, whereas Pax3/ 7 did not inhibit their activity. As PAX/FOXO1A and Pax3/7DN both inhibit myogenic differentiation, which is normally associated with Figure 5 . PAX3/FOXO1A or PAX7/FOXO1A suppress activity of MyoD-target genes. C2C12 cells were infected with the indicated retrovirus (RV), then transfected with the reporter construct and Renilla luciferase plasmid pRL (Promega) as a control, using Lipofectamine LTX. The p34 reporter has Tk-nlacZ controlled by multimerized Pax3/7-binding sites, so it measures the transcriptional activity of Pax3/7. The p34 activity, measured using the Beta-Glo Assay (Promega), was increased in proliferating C2 myoblasts infected with PAX3F-RV, PAX7F-RV, Pax3 or Pax7 2 days previously. By contrast, constitutive expression of Pax3DN or Pax7DN resulted in a significant decrease in p34 activity (a). To evaluate activity of MyoD-target genes, C2C12 cells were infected with RV, transfected with a MyoD-responsive reporter, and stimulated to differentiate for 4 days before measuring luciferase activity, using the dual-Luciferase reporter Assay (Promega) (b --d). Constitutive expression of Pax3 or Pax7 did not decrease the activity of the myogenin (b) or MCK (c) reporters, while PAX3F-RV-or PAX7F-RV-infected cells had reduced luciferase activity, as did Pax3DN-RV-or Pax7DN-RV-infected cells. The MCK reporter was also suppressed when control-RV-infected cells were transfected with a dominant-negative MyoD construct (MyoD DN). Activity of the p21 reporter was also decreased by PAX3/FOXO1A (PAX3F-RV) or PAX7/FOXO1A (PAX7F-RV) in differentiated cells. Myogenin-luciferase (e) levels were unaltered in C3H10T1/2 fibroblasts expressing PAX3F-RV, PAX7F-RV, Pax3 or Pax7. Results are mean firefly luciferase or b-galactosidase activity normalized to control Renilla luciferase activity ± s.e.m. from at least five transfections. Values are expressed as fold activation relative to the reporter level in transfected control-RV infected cells where an asterisk denotes significantly different (Po0.05) from reporter levels in control-RV-infected cells.
an increase in the transcriptional activity of MyoD, the effects on these MyoD-responsive reporter constructs could be an indirect consequence of lack of differentiation. However, in non-myogenic fibroblast cell lines that lack MyoD, reporter activity remained unaltered by all Pax constructs. Interestingly, PAX3/FOXO1A can activate MyoD in fibroblastic cell lines, but the degree of subsequent myogenic differentiation varies between studies from none, through to fusion into large multinucleated myotubes. 29 --31 PAX3/FOXO1A can also inhibit MyoD-mediated myogenic conversion of fibroblasts, 26, 29 but this effect is MyoD-specific, as PAX3/ FOXO1A does not have substantial effects on myogenindependent myogenic conversion.
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PAX3/FOXO1A is a more potent activator of a Pax3/7 reporter construct (p34) than PAX7/FOXO1A, but although PAX3/FOXO1A is more potent than Pax3, 3 PAX7/FOXO1A and Pax7 induced p34 to a similar level. These differences in transcriptional potency may be related to the poorer prognosis of ARMS containing PAX3/ FOXO1A, compared with those with PAX7/FOXO1A. 49 Transcriptional activation by PAX3/FOXO1A is required to prevent myoblast differentiation, as mutant species that are unable to bind DNA are compatible with differentiation. 26 Furthermore, PAX3/FOXO1A is more abundant and stable than Pax3 1,2 and localizes exclusively to the nucleus, 50 which may also add to its transcriptional potency. However, although both PAX/FOXO1A and Pax3/7 can augment MyoD levels, 12, 14 only PAX/FOXO1A inhibits differentiation. Gene targets of PAX3/FOXO1A and PAX3 are not identical; 5, 7 thus, repression of MyoD transcriptional activity likely occurs through regulation of a largely different cohort of gene targets not highly activated/recognized by native PAX3 or PAX7. The overall effect of PAX/FOXO1A in preventing myogenic differentiation though, is more akin to that of the Pax3/7DN constructs. However, the mechanism whereby differentiation is inhibited is different, as Pax3/7DN versions suppress MyoD expression, whereas PAX/ FOXO1A acts downstream of MyoD. . 'Negative' represents the negative control where an equal volume of total protein extract was directly incubated with the beads without being immunoprecipitated with MyoD antibody. Stable C2C12 clones expressing a forced active heterodimer of MyoDBE12 were infected with retrovirus and then cultured in differentiation medium for 4 days, fixed and co-immunostained for eGFP (green) and troponinT (red), and counterstained with DAPI (4,6-diamidino-2-phenylindole). MyoDBE12 stable cells infected with PAX3F-RV or PAX7F-RV failed to express troponinT and remained unfused (c). Scale bar represents 50 mm. MyoDBE12 stable C2C12 cells were infected with retrovirus, transfected with a MyoD-responsive reporter and stimulated to differentiate for 4 days before measuring luciferase activity (d and e). PAX3/FOXO1A or PAX7/FOXO1A suppressed myogenin (d) and MCK (e) luciferase-reporter activity even in the presence of MyoDBE12. Results are mean firefly luciferase activity normalized to control Renilla luciferase activity ± s.e.m. from at least 8 transfections. Values are expressed as fold activation relative to the reporter level in transfected control-RV infected cells, where an asterisk denotes significantly different (Po0.05) from control-RV infection.
PAX3/FOXO1A and PAX7/FOXO1A inhibit MyoD-target genes F Calhabeu et al
MyoD transcriptional activity is regulated by various posttranslational events. 32 However, PAX/FOXO1A did not affect the localization or phosphorylation of MyoD. The MyoD promoter (along with those of myogenin and Mrf4) contains MEF2-binding sites that amplify and maintain their expression, and augment the myogenic activity of MyoD. 32, 51 Moreover, a DN Mef2A inhibits myogenin expression and prevents terminal differentiation. 52 We found that Mef2 is expressed in many cells during the early stages of myogenic differentiation in satellite cells (likely Mef2a since the antibody strongly recognises this isoform), but PAX/FOXO1A inhibits this Mef2 induction, which would affect the ability of MyoD to activate its target genes. However, these effects on Mef2 levels may be an indirect consequence of the general lack of differentiation.
Dimerization of MyoD with E-protein (E12/47) is also a required step to activate transcription targets and initiate muscle differentiation, 32 but MyoD retained its ability to associate with E-protein in myoblasts expressing PAX/FOXO1A. This is consistent with previous studies showing MyoD interaction with E-proteins in several RMS cell lines, 16 although co-expression of MyoD and E-proteins does not induce myogenic differentiation in ARMS. 32 We found that even a forced MyoDBE heterodimer could Figure 7 . PAX3/FOXO1A or PAX7/FOXO1A reduces histone H4 acetylation and RNA polymerase II recruitment at the myogenin promoter. C2C12 cells were infected with indicated retroviruses (RV) and then stimulated to differentiate for 24 h. Total RNA was extracted from infected cells and the levels of MyoD (a) and myogenin (b) transcripts measured by real-time PCR, with values normalized to the reference housekeeping gene Gapdh. MyoD levels were enhanced by PAX3/FOXO1A (PAX3F-RV) or PAX7/FOXO1A (PAX7F-RV) in proliferating myoblasts. However, PAX3/FOXO1A or PAX7/FOXO1A reduced myogenin expression after the induction of differentiation (Po0.05). (b). Chromatin was prepared from C2 myoblasts after 24 h in differentiation medium, when myogenin transcript levels are high in control cells (b). Neither PAX3/ FOXO1A nor PAX7/FOXO1A were enriched at the myogenin locus (c). The verified binding site of the 145-bp regulatory element at À57.5 kb from Myf5 45 was used as a positive control and showed binding of both PAX3/FOXO1A and PAX7/FOXO1A (d). Binding of MyoD at the myogenin promoter was not affected by PAX3/FOXO1A or PAX7/FOXO1A (e). By contrast, the level of acetylation of core histone H4 was reduced (f ), as was binding of RNA polymerase II to the myogenin promoter (g). Representative results from multiple DNA preparations from one of two independent experiments are shown for c --g.
PAX3/FOXO1A and PAX7/FOXO1A inhibit MyoD-target genes F Calhabeu et al not overcome PAX/FOXO1A-dependent inhibition of myogenic differentiation. Interestingly, MyoDBE heterodimer expression in embryonal RMS cell lines strongly induces myogenic differentiation, 53 and as these lines lack the chromosomal translocation that generate PAX/FOXO1A, it again highlights that PAX/FOXO1A acts to inhibit the ability of MyoD to activate its targets genes.
The ability of MyoD to initiate the myogenic programme in nonmuscle cells is associated with chromatin remodelling at the regulatory regions of target genes. 54 We performed ChIP on the myogenin promoter to determine if these epigenetic changes, consistent with active gene expression, were in place and if the transcriptional machinery was assembled. However, although MyoD was present, there was reduced acetylation of histone H4 and decreased occupation of the myogenin promoter by RNA polymerase II. Although PAX/FOXO1A is able to bind defined Pax3/7 consensus sequences in Myf5 regulatory elements, 45, 46 PAX/FOXO1A did not bind at the myogenin promoter, although direct binding via a newly described motif has been reported. 44 MyoD directly interacts with the acetyl-transferase proteins p300 and pCAF, 55 leading to acetylation of histones H3 and H4, facilitating recruitment of RNA polymerase II transcriptional complex. 56 Thus, PAX/FOXO1A inhibits recruitment of histone acetyl-transferases to target genes, likely via interfering with MyoD function.
In summary, MyoD normally activates target genes that initiate a cascade that leads to cell cycle exit and myogenic differentiation. 32 PAX/FOXO1A represses the ability of MyoD to activate some of these target genes, so preventing differentiation. PAX/FOXO1A acts in part, by preventing epigenetic changes and assembly of the transcriptional complex at MyoD-target genes.
MATERIAL AND METHODS

Myofibre isolation
Experimental procedures were carried out under the Animals (Scientific Procedures) Act 1986. Adult (8 --12 weeks old) C57BL/10 or Pax3 GFP/ þ mice (in which eGFP replaces the coding sequence in exon 1---Hayashi et al., manuscript in preparation) were used. Mice were killed by cervical dislocation before the EDL, soleus, biceps, masseter and diaphragm were dissected, and digested in 0.2% collagenase type 1, with myofibres isolated as previously described. 47 Cell culture Myofibres were incubated in plating medium (Dulbecco's modified Eagle's medium with L-glutamine (400 mM) or GlutaMax (Sigma-Aldrich, Dorset, UK) and 10% horse-serum (PAA Laboratories, Somerset, UK), 0.5%. chicken-embryonic-extract (MP Biomedicals, Illkirch, France) and 1% penicillin --streptomycin (Sigma)) at 37 1C in 5% CO 2 . For adherent cultures, myofibres were plated in 6-well plates (Nunc A/S, Roskilde, Denmark) coated with 1 mg/ml Matrigel (BD Biosciences, Bedford, MA, USA) maintained for 3 days in growth medium (Dulbecco's modified Eagle's medium with L-glutamine (400 mM) or GlutaMax, 30% fetal bovine serum, 1% chicken-embryo-extract, 10 ng/ml basic fibroblast growth factor and 1% penicillin --streptomycin), at 37 1C in 5% CO 2 . Myofibres were removed and cells re-plated on Matrigel at low density and maintained in proliferation medium. For differentiation, cells were plated at high density in Matrigel-coated LAB-TEK eight-well chamber slides (Nunc) and cultured in differentiation medium for 4 days (Dulbecco's modified Eagle's medium containing 5% fetal bovine serum).
C2C12 cells were maintained in growth medium (Dulbecco's modified Eagle's medium with L-glutamine (400 mM) or GlutaMax, 10% fetal bovine serum and 1% penicillin --streptomycin). Induction of myogenic differentiation was by incubation in differentiation medium for 3 --4 days at 37 1C. For the stable MyoDBE12 clone, cells were infected with pclBabe-MyoDBE12 retrovirus and selected for 5 weeks with puromycin (3 mg/ml).
Retroviral vectors and reporter plasmids
Human PAX3/FOXO1A and PAX7/FOXO1A 6 were cloned into pMSCV-IRESeGFP 12 to generate pMSCV-PAX3/FOXO1A-IRES-eGFP and pMSCV-PAX3/ FOXO1A-IRES-eGFP, producing PAX3/FOXO1A or PAX7/FOXO1A as a bisitronic message with eGFP. Retroviral constructs encoding wild-type and dominant-negative forms of murine Pax3 and Pax7, and retroviral preparation have been described previously. 11, 36 Satellite cells (5 Â 10 4 ) or C2C12 cells (8 Â 10 4 ) were incubated with retrovirus-containing medium with 4 mg/ml polybrene. Cells were harvested after 10 --12 h and re-plated in Matrigel-coated LAB-TEKH chamber slides. Satellite cells associated with myofibres were exposed to a 1:10 dilution of supernatant after 24 h in culture, and cells analysed 48 h later.
pclBabe-MyoDBE12 forced-dimmer, pCS2-MCK-luciferase reporter, 53 human p21WAF1/CIP1-luciferase reporter, 57 myogenin-luciferase reporter 58 and Pax3/7 reporter (p34) 14 have been described previously.
Immunostaining
Cultures or myofibres were fixed in 4% paraformaldehyde/phosphatebuffered saline for 10 min and permeabilized with 0.5%(v/v) Triton X-100/ phosphate-buffered saline. Cells were blocked with 10% goat-serum and 10% swine-serum/phosphate-buffered saline for 1 h and incubated over- 
Immunoprecipitation and western blot analysis
Infected C2C12 myoblasts were maintained in differentiation medium for 3 days and lysed for 20 min on ice in NonidetP-40 buffer (50 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH7.4, 150 mM NaCl, 5 mM EDTA, pH8.0, 1% Nonidet P-40) containing complete mini protease inhibitor cocktail (Roche Diagnostics Ltd, Burgess Hill, UK), 50 mM NaF, 1 mM sodium orthovanadate and 10 mM sodium pyrophosphate. Lysates were collected, sonicated for 20 s and centrifuged at 15 000 g for 10 min. Equal volumes of extracts were incubated with 4 mg of monoclonal antiMyoD (clone 5.8A, DakoCytomation) or E12/47 (BD Biosciences, Oxford, UK) antibody for 3 h at 4 1C. A volume of 70 ml of protein A-agarose was then added and incubated overnight. Beads were washed with HEPES buffer, resuspended in SDS --polyacrylamide gel electrophoresis sample buffer, and processed for western blot using either rabbit polyclonal anti-MyoD Santa Cruz Biotechnology INC., Heidelberg, Germany or mouse monoclonal anti-E12/47 antibody. Immunocomplexes were detected by chemiluminescence (ECL, GE Healthcare Life Sciences, Buckinghamshire, UK). Primary antibodies used: rabbit polyclonal anti-MyoD (Santa Cruz) and monoclonal mouse anti-b-tubulin (cloneE7, DSHB).
Reporter assays
Transduced C2C12 myoblasts and C3H-10T1/2 fibroblasts were transfected with firefly luciferase or nlacZ reporter plasmids, using Lipofectamine LTX, with Renilla luciferase plasmid pRL (Promega, Corporation, Madison, WI, USA) as a control. After 48 or 96 h transfection, the dual-Luciferase reporter Assay (Promega, corporation) or the Beta-Glo Assay (Promega Corporation) combined with the Renilla luciferase Assay (Promega Corporation) was performed and measured with an Anthos Lucy3 (JENCONS-PLS, West Sussex, UK). Differences between conditions were tested using Student's t-test. 
Chromatin immunoprecipitation
Infected C2C12 myoblasts were fixed in 1% formaldehyde for 10 min, and then incubated in glycine (0.125 M) for 10 min. After centrifugation at 2000 r.p.m. for 5 min at 4 1C, the pellet was suspended in 500 ml lysis buffer (50 mM HEPES, pH7.5; 140 mM NaCl; 1 mM EDTA, 1% Triton-100; 0.1% Na-deoxycholate, protease inhibitors), homogenized and incubated for 20 min at 4 1C. Following centrifugation at 4000 r.p.m. for 5 min at 4 1C, the pellet was suspended in 500 ml of shearing buffer (50 mM Tris-HCl, 10 mM EDTA, 0.1% SDS, 0.5% Na-deoxycholate, protease inhibitors) and incubated for 10 min at 4 1C. Samples were sonicated at 4 1C with five pulses of 20 s using a sonics-vibracell sonicator, centrifuged at 13 000 r.p.m. for 10 min at 4 1C. ChiP-IT Express (Active Motif Europe, La Hulpe, Belgium) was used for some preparations. ChIP was performed with 15 mg of chromatin using rabbit anti-IgG (Invitrogen Life Technologies, Paisley, UK) or antibodies against MyoD (Santa Cruz, sc-760), Pax3/7 (Santa Cruz, sc-7749) or acetylhistone H4 (Millipore Ltd, Watford, UK, 06 --866) or RNA Polymerase II (clone CTD4H8, Millipore). DNA was purified using the QiaQuick PCR purification kit (QIAGEN Ltd) according to the manufacturer's instructions, and DNA eluted with distilled water. ChIP (2 ml) or 1% input DNA was used to quantify PCR with primers: Myogenin promoter (-145/-5), Myog-Fwd , where 'Ct' is the threshold cycles, 'Ab' is the antibody, and 'Input' is the adjusted input genomic DNA (Ct Input --6.644).
